Ian Naya

2.1k total citations
56 papers, 1.5k citations indexed

About

Ian Naya is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Immunology and Allergy. According to data from OpenAlex, Ian Naya has authored 56 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Pulmonary and Respiratory Medicine, 41 papers in Physiology and 3 papers in Immunology and Allergy. Recurrent topics in Ian Naya's work include Asthma and respiratory diseases (40 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (38 papers) and Respiratory Support and Mechanisms (23 papers). Ian Naya is often cited by papers focused on Asthma and respiratory diseases (40 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (38 papers) and Respiratory Support and Mechanisms (23 papers). Ian Naya collaborates with scholars based in United Kingdom, United States and Sweden. Ian Naya's co-authors include Lee Tombs, Roland Buhl, Piotr Kuna, Matthew Peters, David A. Lipson, Antje Prasse, Carin Jorup, A I Manjra, Paul Jones and Dave Singh and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, CHEST Journal and Journal of Allergy and Clinical Immunology.

In The Last Decade

Ian Naya

55 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ian Naya United Kingdom 23 1.3k 1.2k 136 65 57 56 1.5k
Mark Spears United Kingdom 19 674 0.5× 860 0.7× 89 0.7× 139 2.1× 172 3.0× 34 1.1k
Matthew Ball United States 7 270 0.2× 344 0.3× 34 0.3× 60 0.9× 12 0.2× 11 736
Géraldine Cohuet Italy 11 1.1k 0.8× 889 0.7× 6 0.0× 63 1.0× 12 0.2× 20 1.4k
Michele Tari Italy 13 73 0.1× 198 0.2× 211 1.6× 25 0.4× 37 0.6× 26 615
Yang Xie China 13 326 0.2× 85 0.1× 6 0.0× 120 1.8× 51 0.9× 38 608
Marios Kougias Greece 4 145 0.1× 359 0.3× 4 0.0× 72 1.1× 6 0.1× 5 545
John S. Hyde United States 13 100 0.1× 190 0.2× 50 0.4× 53 0.8× 21 0.4× 35 606
Yu-Han Chang Taiwan 14 133 0.1× 98 0.1× 15 0.1× 126 1.9× 15 0.3× 27 599
Sheena Patel United States 14 57 0.0× 283 0.2× 7 0.1× 85 1.3× 26 0.5× 41 671
Danielle Beaumont United Kingdom 11 70 0.1× 107 0.1× 65 0.5× 24 0.4× 22 0.4× 17 433

Countries citing papers authored by Ian Naya

Since Specialization
Citations

This map shows the geographic impact of Ian Naya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Naya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Naya more than expected).

Fields of papers citing papers by Ian Naya

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian Naya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Naya. The network helps show where Ian Naya may publish in the future.

Co-authorship network of co-authors of Ian Naya

This figure shows the co-authorship network connecting the top 25 collaborators of Ian Naya. A scholar is included among the top collaborators of Ian Naya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian Naya. Ian Naya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Han, MeiLan K., Gerard J. Criner, Mark T. Dransfield, et al.. (2021). Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. ERJ Open Research. 7(1). 663–2020. 7 indexed citations
2.
Bjermer, Leif, François Maltais, C. Franz Vogelmeier, et al.. (2020). Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed to Treat Analysis of the EMAX Trial. A3326–A3326.
3.
Maltais, François, Ian Naya, Claus Vogelmeier, et al.. (2020). Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial. Respiratory Research. 21(1). 280–280. 10 indexed citations
4.
Naya, Ian, Lee Tombs, David A. Lipson, I. Boucot, & Chris Compton. (2019). Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis. Respiratory Research. 20(1). 60–60. 10 indexed citations
5.
6.
Naya, Ian, Lee Tombs, David A. Lipson, & Chris Compton. (2018). Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis. Advances in Therapy. 35(10). 1626–1638. 11 indexed citations
7.
Tombs, Lee, Michael J. Asmus, I. Boucot, et al.. (2018). Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials. Drugs & Aging. 35(7). 637–647. 5 indexed citations
8.
Maleki-Yazdi, M. Reza, Dave Singh, Antonio Anzueto, et al.. (2016). Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials. Advances in Therapy. 33(12). 2188–2199. 37 indexed citations
9.
Small, Mark, Tim Holbrook, Robert Wood, et al.. (2016). Prevalence and burden of dyspnoea among COPD patients in Japan. International Journal of Clinical Practice. 70(8). 676–681. 7 indexed citations
10.
Singh, Dave, M. Reza Maleki-Yazdi, Lee Tombs, et al.. (2016). Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. International Journal of COPD. Volume 11. 1413–1424. 54 indexed citations
11.
12.
Adner, Mikael, Bengt Larsson, Jesper Säfholm, Ian Naya, & Anna Miller‐Larsson. (2010). Budesonide Prevents Cytokine-Induced Decrease of the Relaxant Responses to Formoterol and Terbutaline, but Not to Salmeterol, in Mouse Trachea. Journal of Pharmacology and Experimental Therapeutics. 333(1). 273–280. 13 indexed citations
13.
Edwards, Steven J, Robyn von Maltzahn, Ian Naya, & Tim Harrison. (2010). Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials. International Journal of Clinical Practice. 64(5). 619–627. 28 indexed citations
14.
Pavord, Ian, Peter K. Jeffery, Yusheng Qiu, et al.. (2009). Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. Journal of Allergy and Clinical Immunology. 123(5). 1083–1089.e7. 50 indexed citations
15.
Buhl, Roland, et al.. (2003). Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respiratory Medicine. 97(4). 323–330. 66 indexed citations
16.
17.
Dahlén, Barbro, A. Roquet, Mark D. Inman, et al.. (2002). Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction. Journal of Allergy and Clinical Immunology. 109(5). 789–793. 39 indexed citations
18.
Prasse, Antje, et al.. (2000). Zafirlukast Improves Asthma Control in Patients Receiving High-Dose Inhaled Corticosteroids. American Journal of Respiratory and Critical Care Medicine. 162(2). 578–585. 160 indexed citations
19.
Chung, Kian Fan & Ian Naya. (2000). Compliance with an oral asthma medication: a pilot study using an electronic monitoring device. Respiratory Medicine. 94(9). 852–858. 26 indexed citations
20.
Laitinen, L. A., et al.. (1997). Comparative efficacy of zafirlukast and low dose steroids in asthmatics on prn beta2-agonists. 10(25). 419–420. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark Spears Breakdown of academic impact, for papers by Matthew Ball Breakdown of academic impact, for papers by Géraldine Cohuet Breakdown of academic impact, for papers by Michele Tari Breakdown of academic impact, for papers by Yang Xie Breakdown of academic impact, for papers by Marios Kougias Breakdown of academic impact, for papers by John S. Hyde Breakdown of academic impact, for papers by Yu-Han Chang Breakdown of academic impact, for papers by Sheena Patel Breakdown of academic impact, for papers by Danielle Beaumont
Rankless by CCL
2026